BioSig Technologies Merges with Streamex for Tokenization

Introduction

BioSig Technologies Inc (Nasdaq: BSGM) is a medical technology and blockchain company headquartered in Westport, Connecticut. Founded in 2009, its PURE EP™ Platform is an FDA 510(k)–cleared, non-invasive Class II device that enhances cardiac signal visualization during electrophysiology procedures. As of July 8, 2025, the stock closed at $7.36, down 36.28%, on a volume of 2,583,679 shares.

Corporate Structure

BioSig employs between 11 and 50 people, according to its LinkedIn profile. Its senior leadership and board bring experience spanning medical devices, finance, blockchain, and commodities:

• Morgan Lekstrom, Chairman and Co-Founder of Streamex, with over 17 years in global commodities and resource development.
• Henry McPhie, Chief Executive Officer, co-founder of Streamex, and former founder of a Solana-based NFT project.
• Ferdinand Groenewald, Interim Chief Financial Officer, a CPA with roles in public and private companies.
• Mitchell Williams, CFA, Chief Investment Officer, with over 20 years of experience at Credit Suisse, OppenheimerFunds, and Wafra Inc.
• Anthony Amato, Director, with executive experience in pharmaceutical consulting and environmental monitoring systems.

Tokenization by Roman Kraft

Developments and News

On May 19, 2025, BioSig filed its quarterly report on Form 10-Q for the period ended March 31, 2025. Two Current Reports on Form 8-K followed: one on May 27 covering executive appointments and strategic agreements, and another on May 30 detailing additional corporate matters.

On June 12, 2025, BioSig signed a definitive share exchange agreement with Streamex Exchange Corporation. The transaction positions the combined entity as one of the largest public holders of gold bullion and aims to tokenize commodities—an addressable market estimated at $142 trillion—on the Solana blockchain. Cantor Fitzgerald & Co., Clear Street LLC, and Needham & Company, LLC served as placement agents, with CIBC World Markets advising.

Financial and Strategic Analysis

As of July 8, 2025, BioSig’s market capitalization reflects a micro-cap profile, and its stock experienced a decline of 36.28%. The Form 10-Q likely details first-quarter revenues, cash flow, and liquidity positions, but specifics were not disclosed in the summaries provided.

Strategically, BioSig is shifting from a focus on medical-device innovation toward blockchain-enabled real-world asset (RWA) tokenization. The Streamex merger incorporates gold bullion holdings and access to commodity markets on-chain. Key considerations include:

• Integration Risk: Aligning medical-device operations with blockchain infrastructure and asset custody.
• Regulatory Environment: Navigating FDA requirements alongside securities and commodities regulations.
• Capital Needs: Funding technology development, tokenization platform rollout, and bullion acquisitions.

Market Position and Industry Context

BioSig occupies a unique intersection of medical technology and blockchain commodities. In the medical-device sector, its PURE EP™ Platform competes with established electrophysiology systems. In the blockchain arena, it joins firms exploring tokenized real-world assets, with a differentiated focus on physical commodities such as gold. As a small-cap public company, BioSig faces competition from both established med-tech manufacturers and emerging blockchain tokenization platforms.

tl;dr

BioSig closed at $7.36 on July 8, 2025, after a 36.28% intraday decline. Its June 12 share exchange with Streamex creates a publicly listed RWA tokenization entity backed by gold bullion and powered by Solana. Placement agents include Cantor Fitzgerald, Clear Street, and Needham, with CIBC advising. The near-term outlook depends on the successful integration of medical-device operations with blockchain infrastructure, regulatory approvals, and the execution of the tokenization platform across commodity markets.